Last reviewed · How we verify
NCT04766320
Study on TIL for the Treatment of r/r Gynecologic Tumors
Phase 1 trial testing Tumor Infiltrating Lymphocytes (TIL) in Gynecologic Cancer in 15 participants. Status unknown.
4 December 2022
Quick facts
| Lead sponsor | Shanghai 10th People's Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 4 January 2021 |
| Primary completion | 4 December 2022 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tumor Infiltrating Lymphocytes (TIL) — full drug profile →
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
Sponsor
Shanghai 10th People's Hospital
Who can join
Adults 18 to 75, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gynecologic tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A, Watkins R, Vilgelm AE. · · 2021 · cited 98× · PMID 34140957 · DOI 10.3389/fimmu.2021.690499 -
Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.
Guo J, Luo N, Ai G, Yang W, et al · · 2022 · cited 10× · PMID 35177415 · DOI 10.1136/jitc-2021-003887 -
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.
Guo J, Wang C, Luo N, Wu Y, et al · · 2024 · cited 7× · PMID 38769543 · DOI 10.1186/s12916-024-03420-0 -
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.
Zhang W, Liu YM, Li D, Liu S, et al · · 2025 · cited 4× · PMID 40458394 · DOI 10.3389/fimmu.2025.1524842 -
Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.
Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, et al · · 2025 · cited 1× · PMID 40981188 · DOI 10.3390/medsci13030190 -
αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors.
Gan Z, Huang J, Duan S, Lin M, et al · · 2025 · PMID 41398151 · DOI 10.1038/s41467-025-67254-x
Verify or expand the search:
- PubMed search for NCT04766320
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tumor Infiltrating Lymphocytes (TIL)
Trials testing the same drug.
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
- NCT06530303 — Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer · Phase 1, PHASE2 · recruiting
- NCT06532799 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer · Phase 1, PHASE2 · recruiting
- NCT06532812 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06538012 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer · Phase 1, PHASE2 · recruiting
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other Shanghai 10th People's Hospital trials
Trials by the same sponsor.
- NCT07528040 — An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With C · not yet recruiting
- NCT07370441 — Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
- NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
- NCT06783296 — Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension · NA · not yet recruiting
- NCT07204496 — A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766320 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai 10th People's Hospital
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766320.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing